Skip to main content
SpringerLink
Log in

Baricitinib bei systemischem Lupus erythematodes

Baricitinib for systemic lupus erythematosus

  • Klinische Studien
  • Published:
Die Innere Medizin Aims and scope Submit manuscript

Graphic abstract

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Karonitsch T, Feierl E, Steiner CW et al (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60:1463–1471

    Article  PubMed  Google Scholar 

  2. Illei GG, Shirota Y, Yarboro CH et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62:542–552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Aringer M, Stummvoll GH, Steiner G et al (2001) Serum interleukin-15 is elevated in systemic lupus erythematosus. Rheumatology 40:876–881

    Article  CAS  PubMed  Google Scholar 

  4. Gadina M, Le MT, Schwartz DM et al (2019) Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology 58(i4):i16

    Google Scholar 

  5. Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392:222–231

    Article  CAS  PubMed  Google Scholar 

  6. Morand EF, Vital EM, Petri M et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401:1001–1010

    Article  CAS  PubMed  Google Scholar 

  7. Petri M, Bruce IN, Dörner T et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401:1011–1019

    Article  CAS  PubMed  Google Scholar 

  8. Dörner T, Tanaka Y, Dow ER et al (2022) Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. Ann Rheum Dis 81:1267–1272

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bereich Rheumatologie, Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Deutschland

    M. Aringer

  2. Lippetal, Deutschland

    S. Nitschmann

Authors
  1. M. Aringer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Nitschmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Aringer.

Ethics declarations

Interessenkonflikt

M. Aringer: Advisory Boards und/oder Vorträge für AbbVie, Astra Zeneca, Galapagos, GSK, Lilly, Pfizer. S. Nitschmann gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autor/-innen keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

C. Bokemeyer, Hamburg

M. Hallek, Köln

C. Jacobshagen, Karlsruhe

W. Lehmacher, Köln

U. Müller-Ladner, Bad Nauheim

H. Wedemeyer, Hannover

M. Wehling, Mannheim

Das Graphic Abstract wurde gestaltet von S. Nitschmann, Lippetal, Deutschland

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aringer, M., Nitschmann, S. Baricitinib bei systemischem Lupus erythematodes. Innere Medizin 64, 815–818 (2023). https://doi.org/10.1007/s00108-023-01547-5

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00108-023-01547-5

Search

Navigation